Login to Your Account

Clinic Roundup

Tuesday, July 23, 2013

• Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said results of a post-mortem brain tissue study using its investigational Fluorine-18-labeled beta-amyloid imaging agent, NAV4694, to compare performance characteristics of the NAV4694 to 11C-labeled Pittsburgh Compound-B, in control and Alzheimer's disease brain tissue concluded that, although the molecules share structural similarity, NAV4694 better differentiated amyloid deposition associated with Alzheimer's. Results were presented recently at the Alzheimer's Association International conference in Boston.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription